HomeSample Page

Sample Page Title



Vicore Pharma Holding AB (publ), unlocking the potential of a brand new class of drug candidates, angiotensin II kind 2 receptor agonists (ATRAGs), as we speak introduced optimistic outcomes of the COMPANION research (NCT05330312), investigating the efficacy of AlmeeTM, a 9-week digital cognitive behavioral remedy (CBT) accessed by means of a smartphone or pill.

The research met its main endpoint, change from baseline in GAD-7 anxiousness scores, with a statistically vital 2.7-point enchancment within the group handled with Almee in comparison with management, the place a change in GAD-7 rating of greater than 1.8 factors is taken into account clinically significant. The GAD-7 scale is extensively utilized in scientific apply as an evaluation device for anxiousness; scoring ranges from 0 to 21 with 4 ranges spanning minimal anxiousness (0 to 4) to extreme (15 to 21). The noticed 2.7-point enchancment displays promising efficacy in lowering anxiousness ranges and providing tangible aid to people dealing with pulmonary fibrosis (PF). High quality of life, measured by the Okay-BILD, was a key secondary endpoint and improved by 4.4 factors in comparison with management, and the Okay-BILD psychological area improved by 6.5 factors.

The COMPANION research enrolled 108 contributors from throughout america in a randomized, managed, parallel-group scientific investigation evaluating the impression of Almee on the psychological symptom burden in adults identified with pulmonary fibrosis. Residing with an epidemic for which there’s at present no healing therapy accessible has a adverse impression on psychological well being and high quality of life; the purpose of Almee is to offer customized and accessible psychological help for these sufferers.

“It is rather encouraging to see a digital CBT demonstrating a transparent scientific profit for people affected by the psychological well being burden that accompanies pulmonary fibrosis,” stated COMPANION research Principal Investigator Dr. Maureen Horton, Professor of Pulmonary and Essential Care Medication Johns Hopkins College College of Medication, retired. “Offering behavior-modifying instruments that improve high quality of life represents a brand new addition to a complete therapy method for sufferers dwelling with this devastating illness.”

We’re so happy to see these optimistic ends in the COMPANION pivotal research,  and consider that Almee can play a key function together with molecular therapies to deal with the struggling of people with pulmonary fibrosis in a holistic means.”

Ahmed Mousa, Chief Govt Officer, Vicore

Vicore plans to current full outcomes from the COMPANION research at a convention in 2024. The corporate will search to advance Almee in partnership with the builders of permitted and late-stage molecular therapies for the therapy of pulmonary fibrosis, spearheading the continued improvement of innovation in improved remedy with software-molecular mixture therapies.

Almee is topic to medical system regulation in america and Europe and is developed in partnership with Alex Therapeutics.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments